TG Therapeutics, Inc. Recaps Schedule of Data Presentations at the 58th American Society of Hematology Annual Meeting
December 02 2016 - 10:00AM
TG Therapeutics, Inc. (NASDAQ:TGTX), today recapped the schedule of
data presentations for their lead compounds, TGR-1202, the
Company’s once-daily PI3K delta inhibitor, and TG-1101
(ublituximab), the Company’s novel glycoengineered anti-CD20
monoclonal antibody, at the upcoming 58th American Society of
Hematology (ASH) annual meeting, being held December 3-6, 2016, at
the San Diego Convention Center in San Diego, California.
Presentations at the ASH 2016 meeting include the following:
Oral Presentations:
- Title: Silencing c-Myc Translation as a Therapeutic Strategy
through Targeting PI3K Delta and CK1 Epsilon in Hematological
Malignancies
- Abstract Number: 291
- Oral Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and
Biologic Agents: Cell Signaling
- Date and Time: Sunday, December 4, 2016; 7:30 AM - 9:00
AM PT
- Presentation Time: 8:00 AM PT
- Location: San Diego Convention Center, Room 5AB
- Presenter: Changchun (George) Deng, MD, PhD, Columbia
University, New York, NY
- Title: TGR-1202 in Combination with Ibrutinib in Patients with
Relapsed or Refractory CLL or MCL: Preliminary Results of a
Multicenter Phase I/Ib Study
- Abstract Number: 641
- Oral Session: 642. CLL: Therapy, excluding Transplantation:
Targeted Therapy: Novel Agents and Combinations
- Date and Time: Monday, December 5, 2016; 7:00 AM - 8:30
AM PT
- Presentation Time: 8:00 AM PT
- Location: San Diego Convention Center, Room 5AB
- Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute,
Boston, MA
- Title: Preliminary Results from a Phase I Dose Escalation Trial
of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
- Abstract Number: 1125
- Oral Session: 634. Myeloproliferative Syndromes: Clinical:
Clinical Trials with JAK Inhibitors
- Date and Time: Monday, December 5, 2016; 4:30 PM - 6:00
PM PT
- Presentation Time: 5:00 PM PT
- Location: Marriott Marquis San Diego Marina, Pacific Ballroom
Salons 15-17
- Presenter: Tamara Kay Moyo, MD, PhD, Vanderbilt-Ingram Cancer
Center, Nashville, TN
Posters Presentations:
- Title: Modulation of T Cell Compartment in a Preclinical CLL
Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202
- Abstract Number: 3236
- Session: 642. CLL: Therapy, excluding Transplantation: Poster
II
- Date and Time: Sunday, December 4, 2016 6:00 PM - 8:00 PM
PT
- Location: San Diego Convention Center, Hall GH
- Presenter: Kamira K. Maharaj, BS, Moffit Cancer Center, Tampa,
FL
- Title: Combination of Ublituximab, TGR-1202, and Bendamustine
Demonstrates Significant Activity in Patients with Advanced DLBCL
and Follicular Lymphoma
- Abstract Number: 4197
- Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and
Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from
Prospective Clinical Trials: Poster III
- Date and Time: Monday, December 5, 2016; 6:00 PM-8:00 PM
PT
- Location: San Diego Convention Center, Hall GH
- Presenter: Matthew A. Lunning, DO, University of Nebraska
Medical Center, Omaha, NE
- Title: A Phase I Trial of TGR-1202, a Next Generation
Once-Daily PI3Kδ Inhibitor, in Combination with Brentuximab
Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma
- Abstract Number: 4146
- Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical
Studies: Poster III
- Date and Time: Monday, December 5, 2016; 6:00 PM-8:00 PM
PT
- Location: San Diego Convention Center, Hall GH
- Presenter: Rod Ramchandren, MD, Karmanos Cancer Center,
Detroit, MI
A copy of the above referenced abstracts can be viewed online
through the ASH meeting website at www.hematology.org. Following
each presentation, the data presented will be available on the
Publications page of the Company’s website at
www.tgtherapeutics.com.
TG Therapeutics will also host an investor and analyst reception
on Monday, December 5th, 2016 beginning at 8:00pm PT. The
event will take place at the Marriott Gaslamp, in San Diego,
California, in the Presidio AB Ballroom. An audio recording
of this presentation and accompanying slides will be made available
on the Company’s website following the conclusion of the event.
This event will not be webcast live.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the
acquisition, development and commercialization of novel treatments
for B-cell malignancies and autoimmune diseases. Currently, the
company is developing two therapies targeting hematological
malignancies and autoimmune diseases. TG-1101 (ublituximab) is a
novel, glycoengineered monoclonal antibody that targets a specific
and unique epitope on the CD20 antigen found on mature
B-lymphocytes. TG Therapeutics is also developing TGR-1202, an
orally available PI3K delta inhibitor. The delta isoform of PI3K is
strongly expressed in cells of hematopoietic origin and is believed
to be important in the proliferation and survival of B‐lymphocytes.
Both TG-1101 and TGR-1202 are in clinical development for patients
with hematologic malignancies, with TG-1101 recently entering
clinical development for autoimmune disorders. The Company also has
pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors,
and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is
headquartered in New York City. Cautionary
Statement
Some of the statements included in this press release,
particularly those with respect to anticipating future clinical
trials, the timing of commencing or completing such trials and
business prospects for TG-1101, TGR-1202, the IRAK4 inhibitor
program, the BET inhibitor program, and the anti-PD-L1 and
anti-GITR antibodies may be forward-looking statements that involve
a number of risks and uncertainties. For those statements, we
claim the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995. Among the factors that could cause our actual
results to differ materially are the following: our ability to
successfully and cost-effectively complete preclinical and clinical
trials for TG-1101, TGR-1202, the IRAK4 inhibitor program, the BET
inhibitor program, and the anti-PD-L1 and anti-GITR antibodies; the
risk that early preclinical and clinical results that supported our
decision to move forward with TG-1101, TGR-1202, the IRAK4
inhibitor program, the BET inhibitor program, and the anti-PD-L1
and anti-GITR antibodies will not be reproduced in additional
patients or in future studies; the risk that trends observed which
underlie certain assumptions of future performance of TGR-1202 will
not continue, the risk that TGR-1202 will not produce satisfactory
safety and efficacy results to warrant further development
following the completion of the current Phase 1 study; the risk
that the combination of TG-1101 and TGR-1202, referred to as
TG-1303, will not prove to be a safe and efficacious backbone for
triple and quad combination therapies; the risk that the data (both
safety and efficacy) from future clinical trials will not coincide
with the data produced from prior preclinical and clinical trials;
the risk that trials will take longer to enroll than expected; our
ability to achieve the milestones we project over the next year;
our ability to manage our cash in line with our projections, and
other risk factors identified from time to time in our reports
filed with the Securities and Exchange Commission. Any
forward-looking statements set forth in this press release speak
only as of the date of this press release. We do not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release
and prior releases are available at www.tgtherapeutics.com. The
information found on our website is not incorporated by reference
into this press release and is included for reference purposes
only. TGTX - G
CONTACT:
Jenna Bosco
Vice President, Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024